India High Court Orders Glenmark Response To MSD Appeal By May 22
This article was originally published in PharmAsia News
Executive Summary
A two-judge panel of the Delhi High Court ordered Glenmark to respond by May 22 as Merck Sharp and Dohme continues the appeal process against the India drug maker's generics of Januvia (sitagliptin) and Janumet (metformin/sitagliptin) diabetes drugs.